Similarly, CD19-targeted CAR-T cell therapy has achieved impressive outcomes in relapsed/refractory acute lymphoblastic leukemia (ALL), with complete response (CR) rates reaching up to 90% (27). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.